Claims for Patent: 11,202,752

Summary for Patent: 11,202,752

Title:	Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
Abstract:	Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration ("FDA").
Inventor(s):	Gregory; Jefferson J. (Bristol, TN), Nordsiek; Michael T. (Wayne, PA)
Assignee:	Medicis Pharmaceutical Corporation (Bridgewater, NJ)
Application Number:	13/895,305
Patent Claims:	1. A method of topical and/or transdermal administration of imiquimod for treating genital warts in a mammal, which method comprises: (a) applying an effective amount of a cream containing 3.75% imiquimod on the skin of the mammal once a day every day of the week for a duration of about 8 consecutive weeks; and (b) allowing said imiquimod to remain in contact with the skin for a sufficient time following said application to permit an effective amount of the imiquimod to penetrate the skin to achieve the antiviral effect and to treat the genital warts. 2. The method of claim 1, wherein the formulation further includes a fatty acid selected from the group consisting of: isostearic acid, oleic acid, super purified oleic acid, and linoleic acid. 3. A method of topical and/or transdermal administration of imiquimod to induce interferon biosynthesis to treat genital warts in a mammal, which method comprises: (a) applying an effective amount of a cream containing 3.75% imiquimod on the skin of the mammal once a day every day of the week for about 8 consecutive weeks; and (b) allowing said imiquimod to remain in contact with the skin for a sufficient time following said application to permit an effective amount of the imiquimod to penetrate the skin to achieve the antiviral effect to treat the genital warts. 4. The method of claim 3, wherein the formulation further includes a fatty acid selected from the group consisting of: isostearic acid, oleic acid, super purified oleic acid, and linoleic acid. 5. The method of claim 4, wherein the fatty acid is isostearic acid.